The FDA’s Patient-Focused Drug Development (PFDD) program is part of a broader industry shift toward prioritizing the patient experience in decision-making. eCOA clinical trials help pharma companies deliver on this commitment – but adopting the tools and processes necessary to implement robust eCOA strategies remains challenging.
In this article, we’ll explore how the Within3 Launch Intelligence Platform complements eCOA clinical trial strategies and directly supports launch excellence.
What is eCOA in clinical trials?
The acronym eCOA stands for Electronic Clinical Outcome Assessment. It refers to a method of collecting patient data during clinical trials that utilizes electronic devices over traditional ink-and-paper data collection methods. The aim is to make clinical trials more patient-centric by ‘hearing the patient voice’ through patient-reported outcomes (PROs) – ultimately improving the quality and accuracy of clinical trial data to generate better insights and more informed decision-making.
“eCOA has transformed data collection in clinical trials by prioritizing patient engagement and improving data accuracy… This shift aligns with the growing emphasis on patient-centric research, ensuring that patient voices are effectively integrated into clinical outcomes.”-Clinical Leader
eCOAs have become essential for capturing patient-centered evidence in modern clinical trials – particularly those that follow decentralized or hybrid models.
What are some best practices for eCOA in clinical trials?
The success of any eCOA strategy depends on early planning, cross-functional alignment, and continuous stakeholder feedback. A strong eCOA strategy will ensure your organization is set up with the correct technologies and processes to perform eCOAs, and that staff are appropriately trained both to implement them and extract insights from them.
“Priorities include ensuring data quality and integrity, meeting regulatory requirements, bolstering data security and privacy, and minimizing errors that could compromise patient safety.”-Applied Clinical Trials
The following are some best practices for successful eCOA clinical trial strategies:
- Carefully select tools and technologies: Ensure that the tools and technologies you select comply with FDA/EMA guidelines and can support your study’s assessment types.
- Consider a hybrid deployment approach: Combining in-house devices with a secure BYOD (bring your own device) policy can maximize patient engagement and data quality.
- Monitor data quality for compliance: Automate data monitoring and quality checks to ensure compliance, and implement protocols for handling missing or unclean data.
- Consider patient engagement strategies: Consider ‘gamifying’ aspects of your eCOA strategy – for example, by using achievement badges or progress trackers – to encourage consistent patient engagement.
- Make cultural and linguistic adaptations for multinational trials: If you’re conducting multinational trials, ensure that processes are in place to capture data across multiple languages, or to translate that information once the trial is completed.
- Employ risk mitigation strategies: A backup data collection system can act as a safeguard should your primary method fail.
How does Within3 support eCOA clinical trial strategies?
Within3 supports the success of eCOA strategies by extending their reach and ensuring trial insights flow seamlessly into launch excellence. Here’s how:
Asynchronous clinical trial engagement
Asynchronous or decentralized clinical trials are a means of collecting clinical trial data remotely, utilizing technology to facilitate interactions without requiring the patient to attend in person. Within3’s asynchronous virtual engagements make it possible to capture clinical trial data from practically anywhere while engaging patients, investigators, and other stakeholders across multiple sites and locations.
Trial sponsors can use tools such as moderator dashboards to ensure compliance and encourage ongoing participation, while our in-platform translation functionality effectively solves for the linguistic and cultural adaptations we mentioned previously.
Within3 complements eCOA strategies by facilitating earlier engagement, broader participation, and continuous insight capture from design to in-trial feedback.
The power of Launch Intelligence™
The Within3 Launch Intelligence Platform helps you hear the voice of the patient more clearly than ever before – empowering teams to transform their eCOA clinical trial data into true launch excellence. Launch Intelligence™ brings together the most critical sources of market insight – field activity, HCP engagement, social sentiment, claims data, congress activity, eCOA trial data, and more – into a single, integrated view. Teams get a real-time view of market intelligence, delivering precise, evidence-based answers in minutes, not months.
Within3’s data analysis and insight reporting tools help to maintain the accuracy and quality of your data – supporting your team as you develop eCOA clinical trial strategies. And by generating stronger trial insights, Within3’s Launch Intelligence Platform can also help life science teams identify potential barriers, adapt quickly, build stronger eCOA trials, and ultimately launch with confidence.
Discover how Within3’s Launch Intelligence™ Platform can strengthen your eCOA clinical trial strategies and accelerate launch excellence. Schedule a demo today.
